

Next Edge Biotech and Life Sciences Opportunities Fund

Annual Management Report of Fund Performance – 2021



NEXTEDGE
CAPITAL

This annual management report of fund performance contains financial highlights but does not contain the complete annual financial statements of the Next Edge Biotech and Life Sciences Opportunities Fund (the “Fund”). You may obtain a copy of the annual financial statements at your request, and at no cost, by calling (416) 775-3600 or toll-free at (877) 860-1080, by writing to us at Next Edge Capital Corp., 1 Toronto Street, Suite 200, Toronto, Ontario, M5C 2V6, Canada or by visiting our website at www.nextedgecapital.com or SEDAR at www.sedar.com.

Unitholders may also contact us using one of these methods to request a copy of the investment fund’s proxy voting policies and procedures, proxy voting disclosure record, or quarterly portfolio disclosure.

Caution Regarding Forward-looking Statements

Certain portions of this report, including but not limited to, “Results of Operations” and “Recent Developments”, may contain forward-looking statements about Next Edge Biotech and Life Sciences Opportunities Fund (the “Fund”), including its strategies, risks, expected performance and condition. All statements, other than statements of historical fact, that address activities, events or developments that Next Edge Capital Corp. (the “Manager”) believe, expect or anticipate will or may occur in the future (including, without limitation, statements regarding any targeted returns, projections, forecasts, statements and future plans and objectives of the Fund) are forward-looking statements. These forward-looking statements reflect the current expectations, assumptions or beliefs of the Manager based on information currently available to the Fund.

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Fund to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on the Fund.

Factors that could cause actual results or events to differ materially from current expectations include, among other things, changes in international financial and commodities markets, fluctuations in currency exchange and interest rates, illiquidity of portfolio investments, reduction in availability of leverage, default by counterparties, special risks arising from short sales and investments in forward contracts and other derivatives, unintentional trades, accuracy of analytical models, valuation risks, limitations on redemptions, tax consequences, changes in applicable laws and other risks associated with investing in securities and those factors discussed under the section entitled “Risk Factors” in the Fund’s simplified prospectus.

Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Manager and the Fund disclaim any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Manager believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Management discussion of fund performance

Investment Objective and Strategies

Next Edge Biotech and Life Sciences Opportunities Fund (the “Fund”) is a mutual fund established as a trust under the laws of the Province of Ontario by a declaration of trust dated November 3, 2020 made by Next Edge Capital Corp., in its capacity as trustee of the Fund. The Fund is divided into units of participation (“Units”) representing an interest in the Fund held by unitholders of the Fund (“Unitholders”). The Fund has two classes of Units: Class A Units, and Class F Units.

The Fund started investing according to its investment objective on December 22, 2020.

Investment Objective

The Fund seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally.

The Fund will not change the investment objectives of the Fund without the approval of a majority of Unitholders.

Investment Strategies

The portfolio manager uses the following investment strategies to attempt to achieve the Fund’s investment objective:

- Holdings comprised of a mix of biotechnology and life sciences companies.
- Sector exposure includes biotechnology, speciality pharma, medical devices, medical software and technology, diagnostics, drug delivery, bioinformatics and agricultural, healthcare services and telehealth services.
- Derivatives may be used for hedging purposes, to generate income and return enhancement.

Investment decisions are made by:

- Focusing on companies in early to later stages of clinical development or early commercialization that meet specific criteria and whose data has been subjected to peer reviewed analysis.
- The Fund is managed to seek to attempt to reduce overall portfolio volatility by: further reducing the risk associated with investments in a particular sector by placing option hedges on biotechnology indices; and exiting or hedging a particular position, should the applicable issuer be faced with event risks owing to expected upcoming factors/data/information.
- Collectively hedging to reduce the volatility of a traditionally volatile sector and to generate income and provide return enhancement.

The Fund may invest in or use derivatives for hedging and non-hedging purposes in a manner consistent with the investment objective of the Fund and as permitted by applicable securities legislation. Derivatives to be used by the Fund may include, but are not limited to, non-exchange traded options, forward contracts, futures contracts and swaps. The Fund may also sell short certain securities in accordance with NI 81-102. Short selling will be used selectively and opportunistically. To do this, the Fund borrows the securities it is selling short, and is under an obligation to return the borrowed securities to the lender at a future date. The Fund is required to pay the lender any distribution declared on the borrowed securities, together with any securities borrowing fees. To return the borrowed securities, the Fund purchases these same securities at a later date, with the result that the Fund will generally make a gain on the short sale if the price of the securities has declined by such date. The short selling activities of the Fund are subject to the limitations set out in NI 81-102 (and as such requirements are applicable to alternative mutual funds).

The Fund may enter into securities lending, repurchase and reverse repurchase transactions to earn additional returns, subject, in each case, to limits at least as stringent as those required by Canadian securities regulatory authorities.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Management discussion of fund performance (continued)

As the Fund is considered an “alternative mutual fund” within the meaning of NI 81-102, as noted, it may use strategies generally prohibited to be used by conventional mutual funds, such as the ability to invest more than 10% of its net asset value in securities of a single issuer, the ability to invest in physical commodities or specified derivatives, to borrow cash, to short sell beyond the limits prescribed for conventional mutual funds and to generally employ leverage.

The Fund may depart temporarily from its fundamental investment objectives and will likely invest in cash or cash equivalents in the event of adverse market, economic, political or other considerations.

The Fund is managed by Next Edge Capital Corp. (the “Manager”). The custodian, registrar, transfer agent and valuation agent of the Fund is RBC Investor Services Trust. The registered office of the Fund is located at 1 Toronto Street, Suite 200, Toronto, Ontario, Canada, M5C 2V6.

Risk

The Fund started investing according to its investment objective on December 22, 2020. Effective December 22, 2020, an investment in the Fund is subject to certain risk factors relating to the Fund, as detailed in its Simplified Prospectus. During the year ended December 31, 2021, there were no changes to the Fund that materially affected the overall risk level associated with an investment in the Fund.

Results of Operations

The Fund experienced a decrease in its net assets during the year ended December 31, 2021:

Class of redeemable units	December 31, 2021 NAV per unit (CAD) ¹	December 31, 2020 NAV per unit (CAD)	% return for the year ended December 31, 2021 ¹
A	8.89	10.44	-14.85%
F	8.99	10.44	-13.89%

1. Net assets attributable to holders of redeemable units (“NAV”, or “Net Assets”).

Next Edge Biotech and Life Sciences Opportunities Fund commenced trading according to its investment objective on December 22, 2020 to provide investors with exposure to small-mid cap biotech stocks.

2021 completed the first year since the merger from Next Edge Bio-Tech Plus Fund. Primary among the benefits of this transition was to reduce the previously required heavy weighting of more junior Canadian Biotech companies, and being anchored to a benchmark that was comprised primarily of Cannabis companies and retirement homes, neither of which reflected the mandate of investments the Fund targeted. As a result of the repositioning of the Fund to invest more significantly in late-phase-3 / early-commercial stage biotech companies, the weight of U.S. and foreign companies in the Fund rose from 48% to 68%, while weight in Canadian companies declined from 40% to 28%. That composition is likely to stabilize at the current positioning.

The sector appreciated sharply in the first 6 weeks of 2021, during which Fund’s Class A Units significantly outperformed both the Nasdaq Biotech Index (^NBI) and the S&P Biotech Index (^SPSIBI). The Fund capitalized on the strength and liquidity to dramatically reduce microcap Canadian holdings at opportune prices. At that point, Biotech, along with Clean Energy and Blue-Sky themed companies, COVID-19 beneficiaries and Work-from-Home companies and frothy Meme stocks, all descended into steep bear markets for the remainder of the year. What started out as a promising year, ended as a very disappointing year for the sector. The S&P Biotech index declined -38% off its February peak.

The decline was initially triggered by a defensive rotation out of long-duration small-cap growth, compounded by excessive supply from record IPO and secondary financings, made worse by many high-profile clinical failures, most of which we were fortunate to have side-stepped. In the 4th quarter, the sector came under renewed liquidation pressure that did not distinguish

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Management discussion of fund performance (continued)

between the high-quality late-phase companies that the Fund focuses on owning, companies already reported superior phase 3 data with significant growth ahead and flush with cash; in contrast to the risky, early-stage microcaps with limitless future funding needs and clinical hurdles ahead.

For 2021, the Next Edge Biotech and Life Sciences Opportunities Fund Class A Units declined by -14.85% and the Next Edge Biotech and Life Sciences Opportunities Fund Class F Units by -13.89% vs -20.45% for the S&P Biotech Index (^SPSIBI). The Fund's significant relative outperformance for most of the year shrunk during the 4th quarter as many of the Fund's core, high-quality heavyweight holdings experienced unexplainable declines, not due to fundamental developments, but primarily a function of indiscriminate sector liquidation pressures independent of the merit of the investment. Nevertheless, we trust our process for choosing investments out of a universe of a thousand companies. It has been proven over the decades and validated by the propensity of our holdings that have been acquired by large cap BioPharma companies. Eleven investments made by the Fund's predecessor Fund (Next Edge Biotech Plus Fund) were acquired over the past 5 years and +30 have been acquired over the Fund portfolio manager's career. While the Fund did not benefit from any investments being acquired in 2021, we are mindful that M&A often increases after severe sector drawdowns such as experienced in 2021. That was the case in the 2H:2016, Q1:2019 and Q2:2020.

Over the past two decades, after the prior three times the S&P Biotech Index declined by greater than -15% in a year (2002, 2016, 2018), the sector advanced +44%, +43% and +32% in each of the following years. Companies that the Fund is invested in received nine FDA approvals during 2021, signaling future commercial growth. But that was obscured and unrewarded by the sector weakness. That will change when the market probes for non-economically sensitive growth companies available at compelling valuations.

Recent Developments

2022 began where 2021 left off: with continued significant sector selling, this time joined in by global equity markets. The S&P Biotech Index fell over 16% in January, and achieved over a -46% decline off 2021 peak levels. Such a magnitude of sector bear market has only occurred three prior periods, and only after multiyear +500% bull markets between 1988-1992, 1995-2000 and 2010-2015. No such bull market preceded this severe bear market selloff.

As a result, selective Tech-Bio and Biotech growth companies with rapid revenue growth are available at compelling valuations. In fact, we repositioned the Fund to make room for ten new positions that are down -60% to -80% off levels from a year ago. We are most comfortable positioning during distressed conditions that causes the market to serve up such compelling investment opportunities. That makes us optimistic about 2022, despite the prevailing bleak sentiment and deeply oversold condition that abounds.

Most importantly, we began to see our highest quality midcap investments with rapid revenue growth, rally against the sector and market weakness in January and February 2022. That is encouraging that the market is searching and finally rewarding non-economically sensitive growth, where the Fund is primarily positioned in.

Several proprietary indicators we monitor quantify the extent of undervaluation and deeply oversold status of the biotech sector. First of all, the relative P-E of profitable biotech companies in the S&P 500 is trading at half the market multiple, and sits a level matched only four prior times (1994, 1998, 2010 & 2017), each instance of which led to substantial rallies. In three of four instances, the rallies measured hundreds of percentages. Secondly, the percent of + 300 Nasdaq Biotech Index (^NBI) companies declined below 10%, which has been a threshold to trigger significant rallies over the past two decades. Thirdly, the percent of biotech companies trading below net-cash has surged +452% over the past year, and by +283% for companies trading between 1X and 2X net cash. In other words, uncommon value abounds in the sector providing a significantly favourable risk-reward set up. Finally, the sector has deviated -40% below its 200-day moving average which was the worst reading in six years, and second worst in nineteen years. Similar readings over that period have triggered reversion to the mean.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Management discussion of fund performance (continued)

Related Party Transactions

The Manager is responsible for the day-to-day operations of the Fund and provides management services to the Fund, including the marketing, promotion, and distribution of the Fund; transfer agency services; and unitholder reporting and servicing. In consideration of the management services, the Fund pays management fees, which are accrued for daily, to the Manager based on the average NAV of the applicable class of units of the Fund. The Manager pays for dealer compensation, or service fees, if any, out of management fees.

Total management fees for the year ended December 31, 2021 amounted to \$61,894 (period November 3 to December 31, 2020: \$1,233) with \$15,145 (December 31, 2020: \$1,233) in outstanding accrued fees due to the Manager at December 31, 2021 .

The Fund will pay to the Manager, in respect of each fiscal quarter of the Fund, a performance fee equal to 20% of gain in the NAV per Unit of a Class of Units of the Fund, accrued for on a daily basis, over the preceding fiscal quarter or quarters since a performance fee was last payable, provided that the NAV per Unit of the Fund (including distributions) is greater than all previous values at the end of each previous fiscal quarter in which a performance fee was paid.

Total performance fees for the year ended December 31, 2021 amounted to \$413,912 (period November 3 to December 31, 2020: \$109,299), and \$nil (December 31, 2020: \$109,299) outstanding accrued fees due to the Manager at December 31, 2021 .

The Manager incurs operating expenses on behalf of the Fund and is then reimbursed by the Fund for such expenses.

National Instrument 81-107 Independent Review Committee for Investment Funds ("NI 81-107") requires all publicly offered investment funds, such as the Fund, to establish an independent review committee ("IRC"). Consequently, the Manager has appointed three independent IRC members. The purpose of the IRC is to: (i) review and provide input on the Manager's written policies and procedures that deal with conflict of interest matters; (ii) consider and, if deemed appropriate, approve the Manager's decision on a conflict of interest matter that the Manager refers to the IRC for approval; and (iii) perform such other duties as may be required of the IRC under applicable Canadian securities laws. Additional information about the IRC is available in the Fund's prospectus. Fees are paid to the IRC members for the performance of their duties.

The total remuneration paid to members of the Independent Review Committee allocable to the Fund during the year ended December 31, 2021 was \$30,000 (period November 3 to December 31, 2020: \$nil).

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Financial highlights

The following tables show selected key financial information about the Fund and are intended to help you understand the Fund's financial performance for the year ended December 31, 2021 and period ended December 31, 2020.

Class A³ – Net Assets per Unit (CAD)

For the period ended ¹	December 31, 2021	December 31, 2020
Net Assets per unit, beginning of period	10.44	10.00
(Decrease) Increase from operations		
Total revenue	-	-
Total expenses	(1.14)	(0.14)
Realized gains (losses) for the period	0.28	(0.04)
Unrealized (losses) gains for the period	(1.08)	0.62
Total (decrease) increase from operations	(1.94)	0.44
Distributions		
From net investment income (excluding dividends)	-	-
From dividends	-	-
From capital gains	-	-
Return of capital	-	-
Total distributions	-	-
Net Assets per unit, end of period²	8.89	10.44

Class F – Net Assets per Unit (CAD)

For the period ended ¹	December 31, 2021	December 31, 2020
Net Assets per unit, beginning of period	10.44	10.00
Increase from operations		
Total revenue	-	-
Total expenses	(0.74)	(0.14)
Realized gains (losses) for the period	0.28	(0.04)
Unrealized (losses) gains for the period	(2.01)	0.62
Total (decrease) increase from operations	(2.47)	0.44
Distributions		
From net investment income (excluding dividends)	-	-
From dividends	-	-
From capital gains	-	-
Return of capital	-	-
Total distributions	-	-
Net Assets per Unit, end of period²	8.99	10.44

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Financial highlights (continued)

1. This information is derived from the Fund's audited financial statements for the year ended December 31, 2021 and period November 3 to December 31, 2020.
2. Net Assets and distributions are based on the actual number of units outstanding at the relevant time. The increase (decrease) from operations is calculated based on the average number of units outstanding over the period. Therefore, the beginning of period Net Assets, the increase (decrease) from operations and distributions, if any, will not sum to the end of period Net Assets.
3. The first issuance of Class A Units was on November 3, 2020, but the Fund did not start investing according to its investment mandate until December 22, 2020. The first issuance of Class F Units was on December 22, 2020.

Next Edge Biotech and Life Sciences Opportunities Fund
Annual management report of fund performance – December 31, 2021
Financial highlights (continued)

Class A⁶ – Ratios and Supplement Data:

For the period ended	December 31, 2021	December 31, 2020
Total NAV (CAD 000s) ¹	5,559	5,161
Number of units outstanding ¹	624,997	494,314
Management expense ratio ²	7.21%	52.47%
Management expense ratio before waivers or absorptions ²	7.21%	1.13%
Management expense ratio before performance fees ⁵	3.94%	1.13%
Trading expense ratio ³	2.48%	3.27%
Portfolio turnover rate ⁴	371.05%	10.32%
NAV per unit (CAD)	8.89	10.44

Class F⁶ – Ratios and Supplement Data:

For the period ended	December 31, 2021	December 31, 2020
Total NAV (CAD 000s) ¹	7,438	4,856
Number of units outstanding ¹	827,080	464,938
Management expense ratio ²	4.61%	52.02%
Management expense ratio before waivers or absorptions ²	4.61%	0.00%
Management expense ratio before performance fees ⁵	2.68%	0.00%
Trading expense ratio ³	2.48%	3.27%
Portfolio turnover rate ⁴	371.05%	10.32%
NAV per unit (CAD)	8.99	10.44

1. This information is provided as at December 31, 2021 and 2020.
2. Management expense ratio is based on total expenses (excluding distributions, commissions and other portfolio transaction costs) for the stated period and is expressed as an annualized percentage of daily average net asset value during the period. The management expense ratio is calculated in accordance with Part 15 of NI 81-106.
3. The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net asset value during the period.
4. The Fund's portfolio turnover rate indicates how actively the Fund's portfolio manager manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Fund buying and selling all of the securities in its portfolio once in the course of the year. The higher the Fund's portfolio turnover rate in a year, the greater the trading costs payable by the Fund in the year, and the greater the chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high turnover rate and the performance of the Fund.
5. The first issuance of Class A Units was on November 3, 2020, but the Fund did not start investing according to its investment mandate until December 22, 2020. The first issuance of Class F Units was on December 22, 2020.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Financial highlights (continued)

Management Fees

Annual Management Fees (% of net asset value of the class of the Fund)	
Class	Management Fee^{1,2}
Class A Units	1.00%
Class F Units	0.00%

1. Plus applicable HST.

2. The Manager may from time to time, in its own discretion, waive a portion of the management fee resulting in a reduction of the management fee charged. To the extent a portion of the management fee is waived, the Manager reserves the right to stop such waiver at any time and without notice to, or the consent of, Unitholders.

For its services to the Fund, the Manager is entitled to receive from the Fund a management fee (the “management fee”) at (up to) an annual rate of: (i) 1.00% of the portion of its NAV represented by the Class A Units, and (ii) nil of the portion of NAV represented by the Class F Units, calculated daily and paid monthly in arrears, plus applicable taxes. The Manager uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Fund's Units. The Fund started accruing for management fees on December 22, 2020.

The Fund pays its own operating expenses, other than advertising costs and costs of dealer compensation programs, which are paid by the Manager.

Annual management fees, and a breakdown of the services received in consideration of the management fees, as a percentage of management fees, for the year ended December 31, 2021, are as follows:

Class of Units	Annual Rates	As a percentage of management fees	
		Dealer Compensation	General administration, investment advice and profit
A	1.00%	100.00%	0.00%
F	0.00%	0.00%	100.00%

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Past performance


The performance information shown assumes that all distributions made by the Fund in the periods shown were reinvested in additional securities of the Fund. The performance information shown does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the Fund has performed in the past does not necessarily indicate how it will perform in the future.

The Fund launched November 3, 2020 but did not trade according to its investment objectives until December 22, 2020.


Reported returns are as follows from the first day to the last day of each fiscal period shown.

Year-by-Year Returns¹

Class A



Class F



1. Returns for the period ended December 31, 2020 are from the Fund 's inception date to December 31, 2020. Inception dates used for calculation are November 3, 2020 for Class A and December 22, 2020 for Class F.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Past performance (continued)

Annual Compound Returns

The following table shows the historical annualized compound returns for each Class of units of the Fund, for the periods ended December 31, 2021. There is no guarantee of performance and past or projected performance is not a reliable indicator of future performance. The latest data available at the time of production has been used. Returns may increase or decrease as a result of currency fluctuations.

Percentage Return	1 year	Since Inception ³
Class A units ¹	-14.85%	-9.59%
Class F units ²	-13.89%	-9.36%

1. Class A units were first issued on inception date of the Fund on November 3, 2020, but the Fund did not start investing according to its mandate until December 22, 2020.
2. The first issuance of Class F units was on December 22, 2020.
3. Inception dates used for calculation are November 3, 2020 for Class A units and December 22, 2020 for Class F units.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Summary of investment portfolio

The following shows the Fund's Portfolio breakdown by asset mix, asset class, geography and the top 25 holdings. The Fund's investment portfolio may change due to ongoing portfolio transactions.

December 31, 2021 Portfolio by Asset Mix	% of Net Asset Value	
	Long	Short
United States equity	48.3%	
Canadian equity	28.2%	
International equity	12.9%	
Equity options	5.8%	(1.7%)
Canadian bond	2.0%	
United States bond	1.0%	
Total investments	98.2%	(1.7%)
Cash and cash equivalents ¹	3.9%	
Other net liabilities	(0.4%)	
Total net asset value	101.7%	(1.7%)

December 31, 2021 Portfolio by Industry	% of Net Asset Value	
	Long	Short
Pharmaceuticals and biotechnology	71.7%	(1.7%)
Healthcare equipment and services	15.7%	
Equity options	5.8%	
Biotechnology	2.0%	
Canadian bond	2.0%	
United States bond	1.0%	
Total investments	98.2%	(1.7%)
Cash and cash equivalents ¹	3.9%	
Other net liabilities	(0.4%)	
Total net asset value	101.7%	(1.7%)

December 31, 2021 Portfolio by Country	% of Net Asset Value	
	Long	Short
United States	52.6%	(1.7%)
Canada	32.6%	
International	13.0%	
Total investments	98.2%	(1.7%)
Cash and cash equivalents ¹	3.9%	
Other net liabilities	(0.4%)	
Total net asset value	101.7%	(1.7%)

1. Cash and cash equivalents are shown in total as one position.

Next Edge Biotech and Life Sciences Opportunities Fund

Annual management report of fund performance – December 31, 2021

Summary of investment portfolio (continued)

Top 25 Long Positions

Issuer	% of Net Asset Value
Exelixis Inc.	5.2%
Microbix Biosystems Inc.	4.1%
Apellis Pharmaceuticals Inc.	4.0%
Phathom Pharmaceuticals Inc.	3.9%
SQI Diagnostics Inc.	3.7%
Incyte Corp.	3.4%
NuVasive Inc.	3.3%
Albireo Pharma Inc.	3.1%
Alector Inc.	3.1%
Alkermes PLC	2.8%
ProQR Therapeutics NV	2.8%
MeiraGTx Holdings PLC	2.8%
Biogen Inc.	2.8%
Opsens Inc.	2.7%
Aurinia Pharmaceuticals Inc.	2.6%
CRISPR Therapeutics AG	2.6%
BioVie Inc.	2.6%
Personalis Inc.	2.4%
Sangamo Therapeutics Inc.	2.4%
Medicenna Therapeutics Corp.	2.3%
FibroGen Inc.	2.2%
ClearPoint Neuro Inc.	2.2%
Imagin Medical Inc. Private Bond, April 22, 2022	2.1%
Immune Bio Inc.	2.0%
Orchard Therapeutics PLC	2.0%
	73.0%

Top 25 Short Positions¹

Issuer	% of Net Asset Value
Biogen Inc.	(1.3)
Spdr S&P 500 ETF Trust	(0.3)
Meiragtx Holdings PLC	(0.1)
Intercept Pharmaceuticals	-
	(1.7)
Net Asset Value of Next Edge Biotech and Life Sciences Opportunities Fund as at December 31, 2021	\$12,996,985
	CAD

1. These are all of the Fund's short positions as at December 31, 2021 .

Next Edge Biotech and Life Sciences Opportunities Fund

General information

MANAGER AND PRINCIPAL DISTRIBUTOR

Next Edge Capital Corp.
1 Toronto Street, Suite 200
Toronto, ON M5C 2V6

Telephone: (416) 775-3600
Fax: (416) 775-3601
Toll Free: 1 (877) 860-1080

www.nextedgecapital.com

CUSTODIAN, REGISTRAR, TRANSFER AGENT AND VALUATION AGENT

RBC Investor & Treasury Services
155 Wellington Street West
Toronto, ON M5V 3H6

www.rbcits.com

BROKER

BMO Capital Markets Prime Brokerage
100 King Street West, 6th Floor
Toronto, ON M5X 1H3

www.bmocm.com

CIBC Capital Markets Prime Brokerage
161 Bay Street
Toronto, ON M5J 2S8

www.cibccm.com

AUDITORS

Ernst & Young LLP
100 Adelaide Street West, P.O. Box 1
Toronto, ON M5H 0B3

www.ey.com

LEGAL COUNSEL

Fasken Martineau DuMoulin LLP
333 Bay Street, Suite 2400
Toronto, ON M5H 2T6

www.fasken.com

Next Edge Capital Corp.
1 Toronto St., Suite 200
Toronto, ON M5C 2V6

Tel: 416 775-3600
Fax: 416 775-3601

www.nextedgecapital.com